Lipid droplets (LDs) are ubiquitous fat storage organelles and play key roles in lipid metabolism and energy homeostasis; in addition, they contribute to protein storage, folding and degradation.
Summary
Lipid droplets (LDs) are ubiquitous fat storage organelles and play key roles in lipid metabolism and energy homeostasis; in addition, they contribute to protein storage, folding and degradation.
Yet, a role for LDs in the nervous system remains largely unexplored. We discuss evidence supporting an intimate functional connection between LDs and Motor Neuron Disease (MND) pathophysiology, examining how LD functions in systemic energy homeostasis, in neuron-glia metabolic coupling and protein folding/clearance may affect or contribute to disease pathology.
An integrated understanding of LD biology and neurodegeneration may open the way for new therapeutic interventions.

The Basics
Motor Neuron Diseases (MNDs) are characterized by the gradual degeneration and death of motor neurons (MNs), resulting in progressive paralysis and muscle atrophy. Amyotrophic Lateral Sclerosis (ALS) is a fatal disease and the most common MND, with a worldwide annual incidence of ~1.9 per 100,000 individuals (Arthur et al., 2016) . A plethora of genes with a causative role in ALS have been identified (Renton et al., 2014) . Among the cellular processes implicated in ALS pathophysiology are ER stress and protein clearance, neuron-glia metabolic coupling and energy homeostasis (Schmitt et al., 2014; Taylor et al., 2016) . However, how alterations in these processes contribute to the disease remains poorly understood. Recently, connections have emerged between MNDs, including ALS, and lipid droplets (LDs), the cellular organelles for fat storage, possibly providing a new perspective for understanding disease-related mechanisms.
LDs are ubiquitous organelles with a unique structure: a core of neutral lipids (triacylglycerols (TAGs) and sterol esters) surrounded by a monolayer of phospholipids and proteins. LDs originate from the ER and, when lipids are needed, they are turned over by cytoplasmic lipases and autophagy. Mechanisms and regulation of LD biogenesis, growth, and turnover are active areas of investigation (Qi et al., 2017; Schulze et al., 2017; Walther et al., 2017) .
LDs play critical roles in cellular processes also implicated in ALS pathophysiology.
Foremost is their role in energy homeostasis, as they provide Fatty Acid (FA) fuel for ATP production. Emerging evidence also links LDs to neuron-glia metabolic coupling (Liu et al., 2017) .
Furthermore, LDs are involved in the resolution of ER stress and the clearing of protein aggregates (Welte, 2015; Welte and Gould, 2017) . Genetic studies suggest that this overlap between LD functions and cellular processes implicated in ALS is not mere happenstance: many genes responsible for ALS, as well as for the MND Hereditary Spastic Paraplegia (HSP), play important roles in LD biology; on the other hand, disruption of lipid metabolism and energy homeostasis are prevalent in ALS (see below, Schmitt et al., 2014 ).
Here we discuss the role of LDs in energy homeostasis, glia-neuron metabolic coupling, and protein aggregation/clearance and formulate mechanistic hypotheses on how disruption of these LD-mediated processes could contribute to ALS pathophysiology. Although additional studies are needed to assess the specific role of LDs in ALS and other MNDs, it is conceivable that targeting LD-related processes might lead to novel therapies for these devastating diseases.
LDs in Metabolic Organs and MNDs
Neurons have extremely high energy demands, and LDs are crucial for energy homeostasis in most cells. Might LD dysfunction promote neurodegeneration by disrupting the energy metabolism of neurons? At first glance, such a scenario seems unlikely because neurons derive much of their energy from glucose. However, when glucose is limiting, neurons use energy-rich substrates ultimately derived from the breakdown of FAs. Below, we discuss how LDs in various tissues across the organism could metabolically support MNs. We then contrast this systemic role with a local function in which LDs in glia provide fuel for neighbouring neurons. Finally, we consider whether LD functions beyond energy metabolism could directly affect MNs. The brain lacks fuel stores and relies on a continuous supply of glucose from peripheral organs, especially the liver. When glucose is scarce, the liver coverts Acetyl-CoA produced during FA β-oxidation into ketone bodies (KBs); KBs are transported through the bloodstream to the brain where they are oxidized to produce energy. FAs metabolized in the liver are, in turn, replenished from dietary lipids in the gut or from lipids stored in adipose tissue. In all these tissues, FAs are stored as TAGs in LDs; thus LD dysfunction could indirectly impact MNs. This notion is attractive because many ALS genes are ubiquitously expressed, and non-cell autonomous processes can contribute to neuronal damage in ALS (Ilieva et al., 2009) .
A link between ALS and disrupted organismal lipid metabolism is suggested by emerging data on TDP-43, a ubiquitous protein encoded by the ALS10 gene. TDP-43-mediated ALS may be caused by either loss of its normal function, gain of new toxic functions, or possibly a combination of both (Polymenidou and Cleveland, 2017; Robberecht and Philips, 2013) . TDP-43 overexpressing mice display neurological symptoms, motor deficits, increased fat accumulation, and adipocyte hypertrophy (Stallings et al., 2013) ; depleting TDP-43 postnatally in mice causes weight loss, body fat reduction, decreased adipocyte LD content, increased FA consumption, and rapid death (Chiang et al., 2010) .
What is the mechanistic basis for these profound physiological changes? In skeletal muscles, TDP-43 depletion blocks insulin-induced trafficking of the glucose transporter Glut4 to the plasma membrane, by downregulating the Rab-GTPase-activating protein TBC1D1.
Consequently, impairment in glucose uptake induces a metabolic switch towards lipids for energy production. Elevated FA consumption and oxidation by skeletal muscles presumably explain increased fat mobilization from adipose tissue (Chadt et al., 2008; Chiang et al., 2010) . We speculate that TBC1D1 might even affect fat storage directly as the related isoform AS160/TBC1D4 regulates both Glut4 translocation and LD growth in adipocytes (Wu et al., 2014) . In a yeast model for ALS, TDP-43 toxicity is enhanced by depletion of seipin (Armakola et al., 2012) . Seipin has a prominent role in LD biogenesis and growth and is the causative gene of two MN disorders: dHMNV and Silver syndrome (Welte et al., 2015) . Intriguingly, the hVAPB/ALS8 gene also controls Glut4 trafficking, both in myoblasts and adipocytes, and affects LD size, number and composition (Al-Anzi et al., 2015; Foster et al., 2000; Jansen et al., 2011) . Mutations in genes controlling LD biogenesis/dynamics modify ALS8 phenotypes in flies (Sanhueza et al., 2015) , and in C. elegans and mice, VAPB depletion induces LD accumulation and clustering in muscles (Han et al., 2013) . In humans, mutations in spatacsin cause ALS and the MND HSP11, and its loss in mice induces MN degeneration, muscle atrophy and a decrease in the steady-state number of LDs, possibly due to defective clearance of lipids by lysosomes (Branchu et al., 2017) .
Evidence pointing to a metabolic switch from glucose towards lipids is also emerging in SOD1 mouse models of ALS: their spinal cord neurons display decreased glucose usage (Miyazaki et al., 2012) , and a fat-rich diet restores normal body mass, delays disease onset and MN degeneration, and extends life expectancy (Schmitt et al., 2014) . Consistent with a change in fuel preference in SOD1 mice, denervation of glycolytic muscle fibres, an early pre-symptomatic event, is preceded by increased expression of lipid-handling genes (Palamiuc et al., 2015) . Increased FA requirements may explain why hyperlipidaemia positively correlates with survival in ALS patients and why they exhibit enhanced circulating levels of KBs (Schmitt et al., 2014) .
Collectively, emerging evidence links ALS to systemic disruption of lipid metabolism ( Figure 1A ), though it remains to be established whether LD defects contribute to disease pathology or play more direct causative roles. We propose that LD dysfunction in various peripheral organs could throttle energy delivery to neurons and muscles, an energy supply these cells depend on under disease conditions.
LDs in Glia-Neuron Metabolic Coupling
Neurons also derive fuel substrates from glia. According to the astrocyte-neuron lactate shuttle hypothesis, under conditions of intense neuronal activity, astrocytes -a type of glia -deliver glucose-derived lactate to neurons for ATP production (Belanger et al., 2011) . Neurons can also receive lactate from oligodendrocytes (glial cells in the CNS that myelinate axons), via monocarboxylate transporters (MCTs). MCT1 ablation leads to axon damage and neuronal degeneration, and MCT1 levels are reduced in affected brain regions from ALS patients and in SOD1 mouse models of ALS . Intriguingly, MCTs can also transport KBs (Halestrap, 2012) , and emerging evidence suggests that glia provide KBs as fuel to neurons, suggesting a novel link between LDs and ALS.
KBs are largely supplied by the liver; but like hepatocytes, astrocytes use FAs as primary metabolic fuel and produce large amount of KBs using a ketogenic machinery that is similar in both cell types (Guzman and Blazquez, 2001 ). This machinery requires the sequential action of three enzymes to transport FAs from the cytosol to the mitochondrial matrix. CPT1 (carnitinepalmitoyltransferase1) on the outer mitochondrial membrane conjugates carnitine with FAs; CACT (carnitine-acylcarnitine translocase) transfers acylcarnitine across the inner mitochondrial membrane where CPT2 conjugates FAs back to Coenzyme-A for subsequent β-oxidation. Inside mitochondria, acetyl moieties condense to generate KBs. In vivo, loss of CPT2 leads to increased starvation sensitivity and reduced life span of Drosophila adults. Because these phenotypes are reversed by selectively restoring CPT2 expression in glia, it was proposed that KB production and release from glia help power the brain (Schulz et al., 2015) .
Together, these observations support a model in which disruption of KB production from LD-derived lipids or of their delivery may impact energy-dependent processes important for MN function and survival ( Figure 1B) . Consistent with this idea, inactivation of CTP2 in Drosophila leads to selective accumulation of LDs in glia, and glia-specific CPT2 expression reverses this phenotype (Schulz et al., 2015) .
LDs in Neurons
Although it used to be controversial whether neuronal LDs exist at all, they have now been clearly identified in axons of Aplysia (Savage et al., 1987) , neuronal cultures and brain sections of Presence and abundance of neuronal LDs vary tremendously and may depend on variables such as developmental stage, nutrient or environmental conditions. In Drosophila glia, for example, LDs are induced by hypoxia in larvae (Bailey et al., 2015) and by neurodegeneration in adults (Liu et al., 2015) . Sex-related differences in FA metabolism (Bakewell et al., 2006; Hoyenga and Hoyenga, 1982) could explain why cultured neurons isolated from females accumulate more LDs than neurons from males (Du et al., 2009) . Neuronal LDs may also be rare or transient, making their identification particularly challenging. In adult mouse brain, LDs are rarely found, but they prominently accumulate inside neurons when their turnover is impaired by mutations in the TAG hydrolase DDHD2 (Inloes et al., 2014) . DDHD2 mouse knockouts exhibit motor and cognitive dysfunctions with extensive neurodegeneration, and in humans, DDHD2 mutations cause a MND known as HSP54 (Inloes et al., 2014) . DDHD2-depleted neurons exhibit swelling of axons and dendrites, and Drosophila neuro-muscular junctions lacking DDHD2 display fewer active zones, the sites of neurotransmitter release (Schuurs-Hoeijmakers et al., 2012). We therefore speculate that excessive LDs may sequester and disrupt the trafficking of proteins and lipids required for synapse assembly; indeed LDs from mutant brains are associated with several proteins implicated in neuronal function (Figure 2) (Inloes et al., 2018) .
Conversely, LDs in glia are larger and more easily detected than in neurons. Heterogeneity in LD content across a cell population was proposed to promote metabolic specialization. In the liver, some cells accumulate more LDs than their neighbours and, when needed, efficiently deliver FAs to surrounding cells . This heterogeneity may represent a strategy to alleviate the overall risk of lipotoxicity because cells with high LD content and higher levels of reactive oxygen species (ROS) express specialized defence mechanisms against oxidative damage.
Might a similar division of labour also exist within the brain, with glia as the high-lipid content cells? Intriguingly, astrocytes contain higher levels of anti-oxidant molecules and ROSdetoxifying enzymes than neurons (Belanger et al., 2011) .
Indeed, there is direct evidence that LDs in glia protect neighbouring neurons from oxidative stress ( Figure 1B) . In Drosophila adults and mice, mitochondrial dysfunction promotes -via ROS accumulation -increased synthesis of lipids, which are then transferred from neurons to glia and stored in LDs (Liu et al., 2017; Liu et al., 2015) . In Drosophila larvae, increased glial LD content due to ROS accumulation (e.g. under hypoxia conditions) is protective because if glia are unable to make LDs, neurons exhibit increased damage from peroxidation (Bailey et al., 2015) . It was proposed that glial LDs sequester lipids away from the plasma membrane, especially lipids containing polyunsaturated FAs (PUFAs), which are particularly vulnerable to peroxidation by ROS. PUFAs are more protected when incorporated into TAGs within LDs than when they are in phospholipids of cell membranes. During ROS-induced apoptosis, PUFAs of membrane phospholipids are peroxidated while their incorporation into LDs is thought to decrease their toxicity, suggesting that protection from oxidative stress is a general role of LDs (Li et al., 2017) .
This protective role could be relevant for ALS as oxidative stress due to mitochondrial dysfunction is a leading cause of MN injury in ALS (Barber and Shaw, 2010) . Consistently, markers of lipid peroxidation are found in the cerebrospinal fluid of ALS patients and in disease models, suggesting that accumulation of these toxic molecules might contribute to ALS (Simpson et al., 2004; Smith et al., 1998) .
LDs in Protein Aggregation and Clearance
Protein turnover is critical for ALS, as a number of ALS-linked mutations affect genes directly involved in protein clearance and homeostasis (Taylor et al., 2016) . Emerging evidence also suggests that LDs play a fundamental role in protein aggregation and clearance. Below we discuss whether and how LD-mediated control of these processes within neurons could affect their function and survival.
When misfolded or overabundant proteins stress the ER, an elaborate machinery is deployed to deliver them to the ubiquitin-proteasome system for degradation (ERAD or endoplasmic reticulum associated protein degradation). For ApoB-100, a major component of the very low density lipoproteins, proteasome-mediated degradation relies on LDs. Knockdown of Derlin-1, an ER protein coupling the transfer of proteins from the ER lumen to the ubiquitination system, decreases ApoB abundance on LDs. Conversely, knockdown of UBXD8, which binds ubiquitinated proteins and sends them for degradation, increases ubiquitinated ApoB levels on LDs. UBXD8 localizes to LDs and recruits VCP/p97, a member of the (AAA+) family which extracts ubiquitinated proteins from large complexes and delivers them to proteasomes. Various components of the ubiquitin-proteasome system also associate with LDs. These data suggest that Derlin dislocates ApoB to LDs where p97/VCP together with UBXD8 hands ApoB off to the proteasome for degradation. A similar mechanism likely operates for other proteins, e.g., because a wide range of ubiquitinated proteins accumulates upon UBXD8 knockdown (Figure 2) (Ohsaki et al., 2006; Welte and Gould, 2017) .
Of particular relevance to ALS are the findings that the ALS8 protein hVAPB associates with LDs (Cermelli et al., 2006) and controls the degradation of misfolded proteins by binding to a similar molecular cluster which includes Derlin1, VCP/p97 and the UBXD8-like protein FAF1 (Ernst et al., 2016) . Specifically, hVAPB binds TTC39B (Huttlin et al., 2015) (Moldavski et al., 2015) . Relevant to ALS could be the observation that ALS8 causing proteins bind TTC39B more weakly than the wild-type counterpart (Huttlin et al., 2015) .
A possible association between protein aggregates and LDs is also emerging in the nuclear compartment. The connection is through so-called promyelocytic leukemia (PML) nuclear bodies, membrane-less organelles of the nuclear matrix controlling diverse processes including transcriptional activity, cell senescence, and protein degradation (Janer et al., 2006; LallemandBreitenbach and de The, 2010; Zhu and Brangwynne, 2015) . PML bodies are present in close physical proximity to LDs within the nucleoplasm. This association is functionally important since knockdown of the PML isoform PMLII, a key organizer of PML bodies, results in fewer nuclear LDs, whereas its overexpression is correlated with more LDs (Ohsaki et al., 2016) . In the brains of ALS patients, Nuclear Inclusions (NIs) have been found that contain ubiquitin, proteasome components, and PML (Seilhean et al., 2004) . Furthermore, the ALS10 protein TDP-43 forms NIs that overlap with PML bodies (Wang et al., 2002) . Finally, PML proteins selectively interact with several misfolded proteins, including TDP-43, and mark them through SUMOylation for proteasome degradation (Guo et al., 2014) . Although the connection between the ability of the PML protein to degrade misfolded proteins and to control LD biogenesis remains to be determined, given the precedent in the cytoplasm, it is plausible that nuclear LDs are platforms for the turnover of aggregated proteins.
Mechanistic clues concerning LD-assisted protein clearance are emerging. SigR1, the causative gene of a juvenile form of ALS (Al-Saif et al., 2011; Prause et al., 2013) , encodes a protein localized at ER-LD contact sites where it is proposed to compartmentalize neutral lipids and regulate their export from the ER to LDs (Hayashi and Su, 2003) . Here, SigR1 associates with lipid rafts, transiently stable membrane microdomains rich in cholesterol and sphingolipids (Rajendran and Simons, 2005) which are also sites where neurodegenerative proteins accumulate and aggregate (Burke et al., 2013; Di Paolo and Kim, 2011) . Might LD-associated lipid rafts promote the sequestration of aggregated proteins on LDs for subsequent degradation? Although purely speculative, future critical tests of this notion seem worthwhile, as LDs can host lipid raft proteins like caveolins, flotillins and stomatin (Fujimoto et al., 2001; Pol et al., 2004; Rajendran et al., 2007; Umlauf et al., 2004) and because the ER-associated lipid raft protein Erlin 2 is linked to both regulation of LD biogenesis (Wang et al., 2012) and certain MNDs (Al-Saif et al., 2012; Alazami et al., 2011) .
Future Crucial Experiments
Going forward, it will be crucial to determine to what extent disease phenotypes in ALS models are altered by tissue-specific modulation of LD genes. Advanced microscopy and newly developed LD fluorescent markers (Kassan et al., 2013; Wang et al., 2016) will make possible the mapping of neuronal LD dynamics. Additionally, lipidomic and proteomic approaches associated with genetic analyses will lay the ground for a mechanistic understanding of the LD role in MN function and survival. 
